ARA-290 (Cibinetide): What It Is and U.S. Status

What is ARA-290?

ARA-290, also known by the generic name cibinetide, is a synthetic peptide made of 11 amino acids. It is based on a small part of erythropoietin (EPO), the hormone that signals the body to make red blood cells. It has been tested in small clinical trials but is not FDA-approved, and no approved medicine in the United States contains it.

How it works

EPO has two separate jobs. Through its classic receptor it drives red blood cell production. Through a different receptor complex, which researchers call the innate repair receptor, it appears to help protect tissues from injury and inflammation.

ARA-290 copies a small surface region of EPO and was engineered to act on the innate repair receptor without stimulating red blood cell production. A 2014 paper in Molecular Medicine described it as a nonerythropoietic peptide, meaning it does not raise red blood cell counts.

Research and development history

The main clinical research has focused on small fiber neuropathy, a type of nerve damage that causes pain, burning and numbness. In a phase 2b trial published in Investigative Ophthalmology and Visual Science in 2017, 64 people with sarcoidosis-related small fiber neuropathy received cibinetide or placebo for 28 days. The main measure was the area of small nerve fibers in the cornea, the clear front of the eye, which can be imaged with a special microscope. Researchers reported an increase with one of the three strengths tested compared with placebo, and more regenerating nerve fibers in skin samples.

A separate phase 2 study in people with type 2 diabetes and painful neuropathy, published in Molecular Medicine in 2014, gave cibinetide or placebo daily for 28 days. The researchers reported better scores on a neuropathic symptom questionnaire and lower HbA1c, a long-term blood sugar marker, in the cibinetide group.

These were short trials in small groups, and their main results were nerve and laboratory measurements rather than long-term symptoms. In 2013 the European Commission granted cibinetide orphan designation for sarcoidosis. We found no record of a completed phase 3 trial or of a marketing application in the United States or Europe.

U.S. regulatory status

Current status: Investigational – not FDA-approved.

Investigational means ARA-290 has been tested in clinical research but has not been approved by the FDA. It is not available as a prescription medicine in the United States.

On the FDA's list of bulk drug substances nominated for use in compounding (updated May 14, 2026), cibinetide (ARA-290) is in Category 3, "nominated without adequate support." It is not on the 503A bulks list, the list of bulk substances pharmacies may use to compound medicines, and Category 3 substances are not covered by the FDA policy that lets pharmacies use certain Category 1 substances while the agency evaluates them.

Products sold online as "research chemicals" or labeled "for research purposes only" are not approved medicines, and the FDA has not reviewed their identity, purity or quality.

Documented safety information

There is no FDA label for ARA-290. The published phase 2 trials reported no major safety problems during their short study periods, but they were too small and too brief to show rare or long-term risks.

Sport

The WADA 2026 Prohibited List does not name ARA-290. However, its class S2.1.5 prohibits "innate repair receptor agonists," giving asialo EPO and carbamylated EPO as examples, at all times. Because ARA-290 is described in research as acting on this receptor, athletes should check with their anti-doping organization.

Why Peptide Labs does not sell ARA-290

Peptide Labs does not sell this compound. This page is general information, not medical advice. Our Peptide Guide exists to explain what these compounds are and how they are regulated, not to supply them.

Anyone with questions about ARA-290 should speak with a licensed healthcare provider, who can explain the current evidence and the legal status in plain terms.

Related reading

See the full list of compound profiles in the Peptide Guide. Other peptides discussed for recovery include BPC-157 and KPV. For the legal background, read whether peptides are legal in the U.S.